Welireg (belzutifan) — United Healthcare
Von Hippel-Lindau (VHL) disease requiring therapy for RCC, CNS hemangioblastoma, or pancreatic neuroendocrine tumor, not requiring immediate surgery
Initial criteria
- Diagnosis of von Hippel-Lindau (VHL) disease
- Patient requires therapy for one of the following: renal cell carcinoma (RCC) OR central nervous system (CNS) hemangioblastoma OR pancreatic neuroendocrine tumor (pNET)
- Patient does not require immediate surgery
Reauthorization criteria
- Patient does not show evidence of disease progression while on Welireg
Approval duration
12 months